Anti-B. anthracis (Anthrax) Protective Antigen (Obiltoxaximab) - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Obiltoxaximab (Anti-B. Anthracis Protective Antigen) is a chimeric monoclonal antibodyspecifically designed to target the PA component of Bacillus anthracis toxin. It is usedalongside appropriate antibacterial drugs for the treatment and prevention of inhalationalanthrax. By binding to the PA component, Obiltoxaximab prevents the anthrax toxin fromentering and damaging cells, thereby enhancing survival rates in animal models ofinhalational anthrax. This antibody is administered intravenously and must be given inmonitored settings due to the risk of hypersensitivity and anaphylaxis1-3. Obiltoxaximab, also known as ETI-204, is a powerful monoclonal antibody designed to target theprotective antigen (PA) of Bacillus anthracis. It is a high-affinity chimeric deimmunized antibodywith a molecular weight of approximately 148 kDa, combining human constant region sequenceswith deimmunized murine variable region sequences. Obiltoxaximab plays a critical role ininhibiting the assembly of anthrax toxin and preventing the intoxication of target cells. This actionhelps promote survival and limit the spread of bacteria in animal models. As an adjunct therapy, ETI-204 has demonstrated significant efficacy in enhancing survival rates when used incombination with antibiotics. Clinical trials have also shown promising results in terms of itssafety, tolerability, and pharmacokinetics1-3.

≥ 5.0 mg/ml

The protective antigen (PA) of Bacillus anthracis binds to endothelialreceptors on human cells, facilitating the entry of edema toxin and lethal toxin into the hostcells.